Search

Your search keyword '"Helmut Oettle"' showing total 10 results
Start Over Author "Helmut Oettle" Journal oncology research and treatment
10 results on '"Helmut Oettle"'

1. Editorial Board / Contents / Imprint / Guidelines for Authors

Author

Antonello Calderoni, Seong-Jang Kim, Xiangdong Li, Lukas C. Heukamp, Salah-Eddin Al-Batran, Rudolf Morant, Yuan Guo, Uwe Pinkert, Stefan Aebi, Adrian Casty, Christoph Springfeld, Daniel Betticher, Arndt Vogel, Katharina König, R. R. Plentz, Chaoyang Cui, Carola Stadelmann, Martina Becker-Schiebe, Oliver Gautschi, Christa Baumann, Andreas Trojan, Christoph Mamot, Erica Pellicioli, Matthias Sperling, Franziska Aebersold-Keller, Wolfgang Hoffmann, Giannicola DʼAddario, Samuel Chang, Volker Kunzmann, Frank Kullmann, Reinhard Büttner, Jens T. Siveke, Guang Yang, Sonja Jehle-Schwertfeger, Joachim Diebold, Katharina Buser, Helmut Oettle, Claudius Irlé, and Hanno Riess

Subjects
Cancer Research, Medical education, Oncology, business.industry, Medicine, Hematology, Editorial board, business
Published
2015
Full Text
View/download PDF

2. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine

Author

Salah-Eddin Al-Batran, Jens T. Siveke, Arndt Vogel, R. R. Plentz, Helmut Oettle, Christoph Springfeld, Frank Kullmann, Volker Kunzmann, and Hanno Riess

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Paclitaxel, medicine.medical_treatment, Deoxycytidine, Albumins, Germany, Pancreatic cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Expert Testimony, Hyperbilirubinemia, Chemotherapy, Evidence-Based Medicine, Performance status, business.industry, Hematology, Evidence-based medicine, medicine.disease, Gemcitabine, Oxaliplatin, Surgery, Pancreatic Neoplasms, Irinotecan, Treatment Outcome, Folfirinox Regimen, business, medicine.drug
Abstract

In patients with advanced unresectable pancreatic cancer, the prognosis is generally poor. Within recent years, new treatment options such as the FOLFIRINOX regimen (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) or the combination of nanoparticle albumin-bound (nab)-paclitaxel plus gemcitabine have shown a clinically relevant survival benefit over the standard gemcitabine in patients with good performance status. Unfortunately, patients with hyperbilirubinaemia, who constitute a substantial proportion of the pancreatic cancer patients, have been excluded from most clinical studies. Consequently, our knowledge on the appropriate medical treatment of this patient group is limited. In a meeting of German medical oncology experts, the available clinical evidence and own clinical experience regarding the management of patients with advanced pancreatic cancer and hyperbilirubinaemia was discussed. The present publication summarises the discussion outcomes with regard to appropriate management of these patients, including consensus-based recommendations for nab-paclitaxel/gemcitabine treatment, according to the best available evidence. In summary, knowledge of the underlying aetiology of hyperbilirubinaemia and the metabolisation routes of the cytotoxic drugs is crucial before initiating chemotherapy. As effective treatment options should also be made available to patients with comorbid conditions, including hyperbilirubinaemia, the experts provide advice for an initial dose reduction of chemotherapy with nab-paclitaxel/gemcitabine based on the total bilirubin level in patients with biliary obstruction or extensive liver metastasis.

Published
2015
Full Text
View/download PDF

3. Status quo in der Zweitlinientherapie des NSCLC und Ausblick in die Zukunft

Author

Jens T. Siveke, Christoph Mamot, Lukas C. Heukamp, Erica Pellicioli, Uwe Pinkert, Joachim Diebold, Salah-Eddin Al-Batran, Chaoyang Cui, Oliver Gautschi, Frank Kullmann, Hanno Riess, Giannicola DʼAddario, Antonello Calderoni, Carola Stadelmann, Daniel Betticher, Wolfgang Hoffmann, Yuan Guo, Reinhard Büttner, Christa Baumann, Helmut Oettle, Guang Yang, Franziska Aebersold-Keller, Stefan Aebi, Xiangdong Li, Claudius Irlé, R. R. Plentz, Arndt Vogel, Volker Kunzmann, Katharina Buser, Katharina König, Rudolf Morant, Andreas Trojan, Sonja Jehle-Schwertfeger, Christoph Springfeld, Samuel Chang, Adrian Casty, Seong-Jang Kim, Martina Becker-Schiebe, and Matthias Sperling

Subjects
Cancer Research, Oncology, Hematology
Published
2015
Full Text
View/download PDF

4. Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

Author

Uwe Pelzer, Hanno Riess, Bernd Dörken, Jens Stieler, Lars Roll, A. Hilbig, and Helmut Oettle

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Organoplatinum Compounds, Nausea, Leucovorin, Salvage therapy, Phases of clinical research, Adenocarcinoma, Deoxycytidine, Gastroenterology, Folinic acid, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Treatment Failure, Aged, Aged, 80 and over, business.industry, Hematology, Middle Aged, medicine.disease, Gemcitabine, Oxaliplatin, Surgery, Pancreatic Neoplasms, Regimen, Treatment Outcome, Oncology, Female, Fluorouracil, medicine.symptom, business, Progressive disease, medicine.drug
Abstract

Background: This phase II trial investigated the efficacy and safety of oxaliplatin (O), 5-fluorouracil (5-FU), and folinic acid (FA) (OFF) as second-line treatment for patients with metastatic pancreatic adenocarcinoma after failure of first-line gemcitabine treatment. Patients and Methods: 37 patients with confirmed progressive disease on gemcitabine therapy were treated with OFF (O 85 mg/m2 days 8, 22; FA 500 mg/m2, followed by 5-FU 2,600mg/m2 days 1, 8, 15, 22) every 6 weeks. Patients were treated on an outpatient basis and remained on treatment until disease progression. Results: All patients were assessable for toxicity and effectiveness. We observed moderate hematotoxicity, the most common non-hematologic toxicity was neurotoxicity. A total of 12 patients had grade 3 nonhematologic toxicities: nausea and vomiting (4 patients), reversible neurotoxicity (5 patients), and diarrhea (3 patients). No grade 4 toxicities were observed. Median time to progression was 12 (1–125) weeks. Survival in second line was 22 (4–326+) weeks. Overall disease control rate was 49% (complete remission = 3%; partial remission = 3%; stable disease > 12 weeks = 43%). Conclusions: This regimen is feasible and active with an acceptable toxicity profile; it can be safely administered in an outpatient setting. There is an urgent need for further investigation in phase III trials.

Published
2009
Full Text
View/download PDF

5. Band 23, Heft 2, April 2000

Author

D. Hoelzer, R. Pasold, J. Ströhl, F.A. Hoffmann, Ch. Armbruster, S.B. Sobottka, N. Runkel, C. Stöllberger, A. Böhme, S. Grützner, W. Knauf, Helmut Oettle, Hanno Riess, T. Wiegel, M. Brandis, J. Behrens, M. Freund, H. Lassmann, G. Schackert, M. Burian, T. Kühn, H. Wolf, K. Guhr, A. Steinmetz, Ü. Aydemir, M.P. Wirth, K. Rossa, A.U. Schratter-Sehn, R. Kreienberg, A. Gerl, M. Herold, H.-J. Hurtz, Marjanka K. Schmidt, M. Huber, C. Neuchrist, C. Santjohanser, G.-V. Kornek, E. Hiller, W. Hinkelbein, A. Manseck, M. Alfrink, O. Hakenberg, N. Willich, W. Schmidt, J. Kornfehl, A. Franke, K. Koretz, U. Duffner, Chr. Klinkenstein, C. Rübe, Wolf O. Bechstein, S. Palkovic, S. Hahnfeld, S. Höcht, M. Aßmann, W. Wagner, R. Munker, L. Meyer, D. Huhn, D. Hölzel, C.M. Niemeyer, H. Eschenburg, M. Kirsch, J. Steglich, and U. von Grünhagen

Subjects
Cancer Research, Oncology, Hematology
Published
2000
Full Text
View/download PDF

6. 5-Fluorouracil: Synchronous Application of Continuous and Bolus Therapy in Heavily Pretreated Metastatic Colorectal Cancer: A Phase I/II Study

Author

Wolf O. Bechstein, Hanno Riess, L. Meyer, and Helmut Oettle

Subjects
Drug, Oncology, Cancer Research, medicine.medical_specialty, Colorectal cancer, business.industry, media_common.quotation_subject, Hematology, medicine.disease, Bolus (medicine), Phase i ii, Fluorouracil, Internal medicine, medicine, business, medicine.drug, media_common
Abstract

Summary Background: 5-Fluorouracil (5-FU) continues to be a basic drug of standard regimens for the treatment of metastatic colorectal cancer. The opt

Published
2000
Full Text
View/download PDF

7. Vol. 23, Supplement 4, April 2000

Author

Siegfried Seeber, Hanno Riess, Elke Jäger, Peter Reichardt, Helmut Oettle, Mathias Freund, Claus-Henning Köhne, Michael Stahl, Dirk Jäger, Wolf Achterrath, J. Orth, Werner Lichtenegger, S. Casper, U. Gatzemeier, Hansjochen Wilke, G. Klautke, Udo Vanhoefer, D.K. Hossfeld, R. Lipp, Jens-Uwe Blohmer, Alexander Knuth, and Rainer Fietkau

Subjects
Cancer Research, Oncology, Hematology
Published
2000
Full Text
View/download PDF

8. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action

Author

Salah-Eddin Al-Batran, Michael Geissler, Helmut Oettle, and Thomas Seufferlein

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Paclitaxel, medicine.medical_treatment, Disease, Models, Biological, chemistry.chemical_compound, Stroma, Internal medicine, Pancreatic cancer, Albumins, Metastatic pancreatic cancer, medicine, Humans, Nab-paclitaxel, chemistry.chemical_classification, Chemotherapy, Evidence-Based Medicine, business.industry, Hematology, medicine.disease, Antineoplastic Agents, Phytogenic, Neoplasm Proteins, Pancreatic Neoplasms, Treatment Outcome, chemistry, Female, business, Glycoprotein, Carcinoma, Pancreatic Ductal
Abstract

For almost 15 years there has been stagnation in the systemic treatment of patients with pancreatic ductal adenocarcinoma (PDAC). Recently, several developments seem to indicate clinically relevant improvements in the treatment of patients with metastatic disease. One of these developments is the introduction of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) into the firstline treatment of metastatic disease. In this review, underlying preclinical and clinical data are discussed, with a special focus on mechanisms of action, the potential interaction with albumin and calcium-binding matricellular glycoproteins, such as the secreted protein acidic and rich in cysteine (SPARC), as well as the clinical outcome associated with the use of nab-paclitaxel.

Published
2014

9. Aktuelles Programm der DGHO Frühjahrstagung 2009, Berlin

Author

Alper Sevinc, Frank Willeke, Cemile Arikan-Sengul, Hans-Joachim Stemmler, Karoline Horisberger, Jens Stieler, Jochen Heymanns, Hubert Köppler, Matthias W. Beckmann, Lars Roll, Ralf-Dieter Hofheinz, Maria Cristina Tirindelli, Holger Arndt, Ombretta Annibali, Klaus H. Metzeler, Stefan Boeck, Jörg Thomalla, Helmut Oettle, Christoph W. M. Reuter, Ute Krautter, Celalettin Camci, Stefan Zimmermann, Enis Yüney, Martin Mory, Ömer Bender, Fatih Levent Balcı, Jochen Rentschler, Andreas Hausmann, Carolin Mogler, A. Hilbig, Martina Schmaus, Joachim Brade, Mehmet Emin Kalender, Joachim Drevs, K. Wolfgang Neff, U. Mergenthaler, Frederik Wenz, Yavuz Pehlivan, Giuseppe Avvisati, Falk Thiel, Jürgen Debus, Hanno Riess, Annette Pandorf, Jens Soltau, Susanne Oertel, Francesco Marchesi, Gülay Bilir, Klaus G. Parhofer, Stefan O. Schoenberg, Uwe Pelzer, Anja Baumann, Metin Karakok, Christian M. Zechmann, Eike Gallmeier, Klaus Klemm, Hasan Akbulut, Maria Teresa Petrucci, Viktor Grünwald, Dietmar Dinter, Rudolf Weide, Philipp Ivanyi, Jale Metindir, and Bernd Dörken

Subjects
Cancer Research, Oncology, Hematology
Published
2009
Full Text
View/download PDF

10. 1) Zu: Dempke et al.: Diagnostik und Therapie maligner Pleura- und Perikardergüsse. Onkologie 1999;22:526–529 2) Authors’ Reply

Author

M. Herold, C. Stöllberger, W. Knauf, H.-J. Hurtz, U. von Grünhagen, H. Lassmann, C. Santjohanser, C. Neuchrist, A. Manseck, J. Kornfehl, N. Willich, W. Schmidt, W. Hinkelbein, R. Pasold, T. Kühn, M. Burian, D. Hoelzer, M. Kirsch, K. Koretz, S. Hahnfeld, U. Duffner, E. Hiller, M.P. Wirth, C.M. Niemeyer, Ch. Armbruster, L. Meyer, H. Eschenburg, W. Wagner, S.B. Sobottka, O. Hakenberg, M. Aßmann, F.A. Hoffmann, Wolf O. Bechstein, S. Grützner, A. Gerl, M. Brandis, A. Steinmetz, Hanno Riess, C. Rübe, R. Munker, M. Alfrink, K. Rossa, J. Behrens, Marjanka K. Schmidt, M. Freund, G. Schackert, A. Böhme, D. Huhn, D. Hölzel, R. Kreienberg, N. Runkel, A. Franke, Helmut Oettle, M. Huber, H. Wolf, Chr. Klinkenstein, J. Ströhl, G.-V. Kornek, T. Wiegel, J. Steglich, A.U. Schratter-Sehn, S. Palkovic, S. Höcht, K. Guhr, and Ü. Aydemir

Subjects
Cancer Research, Oncology, Hematology
Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results